Janux Therapeutics, Inc.JANXNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advance.

businesswire.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.

247wallst.com

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

zacks.com

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

businesswire.com

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.

zacks.com

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

benzinga.com

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).

reuters.com

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, ‌sending its shares up more than 12% in premarket trading.

businesswire.com

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th.

defenseworld.net

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating on the

defenseworld.net

Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low – Time to Sell?

Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $13.62 and last traded at $13.80, with a volume of 29533 shares traded. The stock had previously closed at $13.83. Wall Street Analysts Forecast Growth JANX has been

businesswire.com

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.

defenseworld.net

32,772 Shares in Janux Therapeutics, Inc. $JANX Purchased by Capital Fund Management S.A.

Capital Fund Management S.A. purchased a new stake in Janux Therapeutics, Inc. (NASDAQ: JANX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,772 shares of the company's stock, valued at approximately $757,000. Capital Fund Management S.A. owned 0.05% of

fool.com

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.

benzinga.com

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

reuters.com

Janux dives as gaps in prostate cancer study data worry investors

Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.

benzinga.com

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.

barrons.com

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer.

defenseworld.net

Ensign Peak Advisors Inc Decreases Holdings in Janux Therapeutics, Inc. $JANX

Ensign Peak Advisors Inc reduced its position in Janux Therapeutics, Inc. (NASDAQ: JANX) by 96.8% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,300 shares of the company's stock after selling 285,450 shares during the quarter. Ensign Peak Advisors Inc's

seekingalpha.com

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance